Predictive Oncology (NASDAQ: POAI) shares Q2 2025 quarterly results update

Rhea-AI Filing Summary

Predictive Oncology Inc. filed a current report stating that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company used this filing to formally furnish the press release, which is included as Exhibit 99.1. This gives investors access to the detailed quarterly performance information through the attached exhibit rather than within the body of the report.

False000144615900014461592025-08-142025-08-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 14, 2025

_______________________________

Predictive Oncology Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-36790	33-1007393
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

91 43rd Street, Suite 110

Pittsburgh, Pennsylvania 15201

(Address of Principal Executive Offices) (Zip Code)

(412) 432-1500

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.01 par value	POAI	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, Predictive Oncology Inc. issued a press release attached hereto as Exhibit 99.1 announcing its financial results for the quarter ended June 30, 2025.

Item 9.01. Financial Statements and Exhibits.

(a) Not applicable.

(b) Not applicable.

(c) Not applicable.

(d) Exhibits

Exhibit No.		Description
99.1		Press release dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Predictive Oncology Inc.
Date: August 14, 2025	By:	/s/ Josh Blacher
		Josh Blacher
		Interim Chief Financial Officer

FAQ

What did Predictive Oncology Inc. (POAI) report in this 8-K filing?

Predictive Oncology Inc. reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1.

Which period do the Predictive Oncology (POAI) results cover in this update?

The financial results referenced in this update cover the quarter ended June 30, 2025.

Where can investors find the detailed Q2 2025 financial results for POAI?

Detailed financial results are provided in the press release dated August 14, 2025, which is attached to the report as Exhibit 99.1.

What exhibit is included with this Predictive Oncology (POAI) 8-K?

The report includes Exhibit 99.1, a press release dated August 14, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Does this Predictive Oncology 8-K include full financial statements?

The report itself does not present full financial statements; instead, it furnishes a press release (Exhibit 99.1) that announces the companys financial results for the quarter.

Who signed the Predictive Oncology (POAI) 8-K report?

The report was signed on behalf of Predictive Oncology Inc. by Josh Blacher, Interim Chief Financial Officer.